Arena's big news at the American Diabetes Association meeting last weekend was that the analysis of the two-year pivotal Phase III BLOOM study data showed that patients were keeping off the weight they were losing on lorcaserin. This of course is terrific and bodes well for a potential partnership, something Arena will need soon, as we have said previously.
It sounds as though potential partners are now waiting for the BLOSSOM results in September. This is, of course, a disappointment to all of us who had hoped the BLOOM results in March might do the trick, but in the current environment, caution is understandable.
Curiously, Jack Lief, CEO of Arena, did the interview trail with Mike Huckman of CNBC, while neither Vivus nor Orexigen agreed to an interview. I could read a lot into these tea leaves, although it's probably nothing. Mike has been critical of Arena's handling of the press in the past, so maybe this was some sort of olive branch.